Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genmab
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
BeOne Medicines
Hoffmann-La Roche
Duke University
M.D. Anderson Cancer Center
Sapience Therapeutics
University of California, Davis
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Inhibrx Biosciences, Inc
M.D. Anderson Cancer Center
University of Colorado, Denver
BioInvent International AB
GlaxoSmithKline
University of Pittsburgh
Sensei Biotherapeutics, Inc.
Cancer Research UK
Ascentage Pharma Group Inc.
Novartis
Roswell Park Cancer Institute
BioAtla, Inc.
OncoC4, Inc.
University of Wisconsin, Madison
Immunophotonics, Inc.
Salubris Biotherapeutics Inc
NGM Biopharmaceuticals, Inc
ENB Therapeutics, Inc
iTeos Therapeutics